Tag Archives: Max Nisen

Tesaro says it’s for sale, but who can afford it






The News: Just ahead of the year’s biggest download of cancer data, the maker of a closely watched drug has put itself up for sale, according to The Wall Street… Read more »

Amgen’s osteoporosis med almost a home run in latest trial; fate now murky on heart safety






The News: Amgen Inc. (Thousand Oaks CA) and UCB SA (Brussels) no longer expect their experimental osteoporosis drug to win US approval this year after a higher rate of serious… Read more »

NIH proves immune to Trump’s budget scalpel






The News: Lawmakers expanded instead of slashed the budget for the National Institutes of Health (NIH) in its bipartisan deal to fund the government earlier this week, essentially snubbing the… Read more »

Anthem defies Wall Street, rivals, with stellar 1Q results pegged to Obamacare business






The News: Anthem Inc. (Indianapolis IN), which has 1.1 million customers in individual Obamacare plans, said it was moving ahead with its 2018 insurance filings but had told state regulators… Read more »

Cardinal Health does face plant on skanky earnings guidance; even deal for some Medtronic assets raises concerns






The News: Cardinal Health Inc. (Dublin OH) struck a deal to buy part of Medtronic PLC’s (Dublin IRL) patient monitoring and recovery unit for $6.1 billion, bringing businesses under Cardinal’s roof… Read more »

Wall Street cheers as Axovant snags biotech star David Hung; failed Alzheimer’s drug not impressed






The News: Axovant Sciences Ltd. (Hamilton Bermuda) announced that former Medivation Inc. (San Francisco) chief executive and founder David Hung has been selected as its next CEO effective April 7, 2017 sending… Read more »

Message to GOP on Trumpcare resuscitation effort: it’s dead; get over it






The News: House Speaker Paul Ryan announced a Republican agreement Thursday (April 6, 2017) on legislative language that he said will bring the chamber closer to passing a bill to… Read more »

GOP can’t handle the truth: millions to lose coverage under Trumpcare






Steve’s Take: Remember President Trump’s pre- and post-election promise, no, it sounded more like a guarantee, of “insurance for everybody?” Then last week, the Trump-backed House bill, when finally unveiled… Read more »

Icahn’s latest target, Bristol-Myers, may play hard-to-get; unless Pfizer comes a courting






The News: Activist investor Carl Icahn just announced his latest target: Bristol-Myers Squibb Co., reports the Wall Street Journal. Bristol-Myers has been the focus of several activist investors in recent… Read more »

Teva reports 4Q earnings surprise; but 2017 guidance seen “through a glass darkly.”






The News: Teva Pharmaceutical Industries Ltd. (Petach Tikva ISR) reported Monday (February 13, 2017) that fourth-quarter sales surged 33% year-over-year to $6.5 billion, topping analysts’ estimates of $6.3 billion. The company… Read more »